Hepatotoxicity of 3,4-methylenedioxyamphetamine and α-methyldopamine in isolated rat hepatocytes: Formation of glutathione conjugates

Archives of Toxicology

Volumn 78, Issue 1, 2004, Pages 16-24

  Carvalho, Márcia ^a   Milhazes, Nuno ^a   Remião, Fernando ^a   Borges, Fernanda ^a   Fernandes, Eduarda ^a   Amado, Francisco ^b   Monks, Terrence J ^c   Carvalho, Félix ^a   Bastos, Maria Lourdes ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF AVEIRO   (Portugal)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Methyldopamine; 3,4 Methylenedioxyamphetamine; Glutathione conjugates; Rat hepatocytes

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; ALPHA METHYLDOPAMINE; GLUTATHIONE; GLUTATHIONE DISULFIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; EVALUATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMEOSTASIS; LIPID PEROXIDATION; LIVER CELL; LIVER TOXICITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; XENOBIOTIC METABOLISM;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; BIOTRANSFORMATION; CELL SURVIVAL; CELLS, CULTURED; DEOXYEPINEPHRINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; HALLUCINOGENS; HEPATOCYTES; LIPID PEROXIDATION; MALE; RATS; RATS, WISTAR;

ANIMALIA; MEDA; VERTEBRATA;

EID: 1442278713     PISSN: 03405761     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00204-003-0510-7     Document Type: Article

References (50)

1. Anderson ME (1985) Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 113:548-555
2. Armstrong RN (1991) Glutathione S-transferases: reaction mechanism, structure, and function. Chem Res Toxicol 4:131-140
3. Bai F, Lau SS, Monks TJ (1999) Glutathione and N-acetylcysteine conjugates of α-methyldopamine produce serotoninergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity. Chem Res Toxicol 12:1150-1157
4. Bai F, Jones DC, Lau SS, Monks TJ (2001) Serotonergic neurotoxicity of 3,4-(±)-methylenedioxyamphetamine and 3,4-(±)- methylenedioxymethamphetamine (Ecstasy) is potentiated by inhibition of γ-glutamyl transpeptidase. Chem Res Toxicol 14:863-870
5. 3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 242:911-916
6. Beitia G, Cobreros A, Sainz L, Cenarruzabeitia E (1999) 3,4-Methylenedioxymethamphetamine (ecstasy)-induced hepatotoxicity: effect on cytosolic calcium signals in isolated hepatocytes. Liver 19:234-241
7. Ben-Shachar D, Riederer P, Youdim MB (1991) Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem 57:1609-1614
8. Bindoli A, Rigobello MP, Galzigna L (1989) Toxicity of aminochromes. Toxicol Lett 48:3-20
9. Bindoli A, Rigobello MP, Deeble DJ (1992) Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic Biol Med 13:391-405
10. Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ (2000) Role of quinones in toxicology. Chem Res Toxicol 13:135-160
11. Carstam R, Brinck C, Hindemith-Augustsson A, Rorsman H, Rosengren E (1991) The neuromelanin of the human substancia nigra. Biochim Biophys Acta 1097:152-160
12. Carvalho F, Remião F, Soares ME, Catarino R, Queiroz G, Bastos ML (1997) d-Amphetamine-induced hepatotoxicity: possible contribution of catecholamines and hyperthermia to the effect studied in isolated rat hepatocytes. Arch Toxicol 71:429-436
13. Carvalho M, Carvalho F, Bastos ML (2001) Is hyperthermia the triggering factor for hepatotoxicity induced by 3,4-methylenedioxymethamphetamine (ecstasy)? An in vitro study using freshly isolated mouse hepatocytes. Arch Toxicol 74:789-793
14. Carvalho M, Carvalho F, Remião F, Pereira MdL, Pires-das-Neves R, Bastos MdL (2002a) Effect of 3,4-methylenedioxymethamphetamine ("ecstasy") on body temperature and liver antioxidant status in mice: influence of ambient temperature. Arch Toxicol 76:166-172
15. Carvalho M, Hawksworth G, Milhazes N, Borges F, Monks T, Fernandes E, Carvalho F, Bastos ML (2002b) Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells. Arch Toxicol 76:581-588
16. Cho AK, Hiramatsu M, Distefano EW, Chang AS, Jenden DJ (1990) Stereochemical differences in the metabolism of 3,4- methylenedioxymethamphetamine in vivo and in vitro: a pharmacokinetic analysis. Drug Metab Dispos 18:686-691
17. DeLeve LD, Kaplowitz N (1991) Glutathione metabolism and its role in hepatotoxicity. Pharmacol Ther 52:287-305
18. Di Mascio P, Murphy ME, Sies H (1991) Antioxidant defense systems: the role of carotenoids, tocopherols, and thiols. Am J Clin Nutr 53:1945-2008
19. Dykhuizen RS, Brunt PW, Atkinson P, Simpson JG, Smith CC (1995) Ecstasy induced hepatitis mimicking viral hepatitis. Gut 36:939-941
20. Ellis A, Wendon J, Portmann B, Williams R (1996) Acute liver damage and ecstasy ingestion. Gut 38:454-458
21. Fineschi V, Centini F, Mazzeo E, Turillazzi E (1999) Adam (MDMA) and Eve (MDA) misuse: an immunohistochemical study on three fatal cases. Forensic Sci Int 104:65-74
22. Hegadoren KM, Baker GB, Bourin M (1999) 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 23:539-553
23. Hegedus ZL (2000) The probable involvement of soluble and deposited melanins, their intermediates and the reactive oxygen side-products in human diseases and aging. Toxicology 145:85-101
24. Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340:384-387
25. Hiramatsu M, Kumagai Y, Unger SE, Cho AK (1990) Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther 254:521-527
26. Khakoo S, Coles C, Armstrong J, Barry R (1995) Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymethamphetamine ("ecstasy") usage. J Clin Gastroenterol 20:244-247
27. Kreth K-P, Kovar K-A, Schwab M, Zanger UM (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of "ecstasy"-related designer drugs. Biochem Pharmacol 59:1563-1571
28. Kumagai Y, Lin LY, Schmitz DA, Cho AK (1991) Hydroxyl radical mediated demethylenation of (methylenedioxy)phenyl compounds. Chem Res Toxicol 4:330-334
29. Lim HK, Foltz RL (1988) In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. Chem Res Toxicol 1:370-378
30. Mannervik B, Danielson UH (1988) Glutathione transferases-structure and catalytic activity. CRC Crit Rev Biochem 23:283-337
31. Marquardt GM, DiStefano V, Ling LL (1978) Metabolism of β-3,4-methylenedioxyamphetamine in the rat. Biochem Pharmacol 27:1503-1505
32. Miller RT, Lau SS, Monks TJ (1995) Metabolism of 5-(glutathion-S-yl)- γ-methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats. Chem Res Toxicol 8:634-641
33. Miller RT, Lau SS, Monks TJ (1996) Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-α-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats. Chem Res Toxicol 9:457-465
34. Miller RT, Lau SS, Monks TJ (1997) 2,5-bis-(glutathion-S-yl)-α- methyldopamine, a putative metabolite of (±)-3,4- methylenedioxyamphetamine, decreases brain serotonin concentrations. Eur J Pharmacol 323:173-180
35. Milroy CM, Clark JC, Forrest ARW (1996) Pathology of deaths associated with "ecstasy" and "eve" misuse. J Clin Pathol 49:149-153
36. Moldéus P, Hogberg J, Orrenius S (1978) Isolation and use of liver cells. Methods Enzymol 52:60-71
37. Monks TJ, Lau SS (1992) Toxicology of quinone-thioethers. Crit Rev Toxicol 22:243-270
38. Ommen BV, Ploemen JHTM, Bogaards JJP, Monks TJ, Lau SS, Bladeren PJV (1991) Irreversible inhibition of rat glutathione S-transferase 1-1 by quinones and their glutathione conjugates. Structure-activity relationship and mechanism. Biochem J 276:661-666
39. Ploemen JH, Ommen BV, Bladeren PJV (1991) Irreversible inhibition of human glutathione S-transferase isoenzymes by tetrachloro-1,4-benzoquinone and its glutathione conjugate. Biochem Pharmacol 41:1665-1669
40. Ploemen JH, Ommen BV, Haan AD, Venekamp JV, Bladeren PJV (1994) Inhibition of human glutathione S-transferases by dopamine, α-methyldopa and their 5-S-glutathionyl conjugates. Chem Biol Interact 90:87-99
41. Reed DJ (1990) Glutathione: toxicological implications. Annu Rev Toxicol 30:603-631
42. Remião F, Carmo H, Carvalho FD, Bastos ML (1999) Inhibition of glutathione reductase by isoproterenol oxidation products. J Enzyme Inhib 15:47-61
43. 2+-induced isoproterenol oxidation into isoprenochrome in adult rat calcium-tolerant cardiomyocytes. Chem Res Toxicol 15:861-869
44. Ricaurte GA, Yuan J, McCann UD (2000) (±)3,4- Methylenedioxymethamphetamine ("ecstasy")-induced serotonin neuro toxicity: studies in animals. Neuropsychobiology 42:5-10
45. Simpson DL, Rumack BH (1981) Methylenedioxyamphetamine. Clinical description of overdose, death, and review of pharmacology. Arch Intern Med 141:1507-1509
46. Spencer JP, Jenner P, Daniel SE, Lees AJ, Marsden DC, Halliwell B (1998) Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem 71:2112-2122
47. van Bladeren PJ (2000) Glutathione conjugation as a bioactivation reaction. Chem Biol Interact 129:61-76
48. Varela-Rey M, Montiel-Duarte C, Beitia G, Cenarruzabeitia E, Iraburu MJ (1999) 3,4-Methylenedioxymethamphetamine ("ecstasy") stimulates the expression of α1 (I) procollagen mRNA in hepatic stellate cells. Biochem Biophys Res Commun 259:678-682
49. Walubo A, Seger D (1999) Fatal multi-organ failure after suicidal overdose with MDMA, "ecstasy": case report and review of the literature. Hum Exp Toxicol 18:119-125
50. Zhang F, Dryhurst G (1994) Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. J Med Chem 37:1084-1098